OPKO Health OPK Q2 2026: Rayaldee Deal Fuels Biggest EPS Beat in Years
As seen on the 24/7 Wall St. homepage on July 27, 2026.
OPKO Health crushed consensus on both lines, posting a loss of just $0.01 per share versus an $0.11 miss estimate and delivering $163.5M in revenue against $131M forecasted. A $29.4M licensing deal with Nicoya on Rayaldee commercialization in Greater China drove the pharmaceutical segment to profitability for the first time in a year, while net losses narrowed 94% year over year to $8.4M.
Continue ReadingShow less
OPKO Health posted a net loss of just $0.01 per share in Q2 2026, obliterating the consensus estimate of an $0.11 loss — a beat of roughly 91%. Revenue came in at $163.5 million against a $131 million forecast, a 25% upside surprise. The standout catalyst was a $29.4 million licensing agreement with Nicoya covering Rayaldee commercialization rights in Greater China, which single-handedly pushed the pharmaceutical segment into profitability for the first time in a year.
The bottom-line improvement was equally striking. Net losses narrowed 94% year over year to $8.4 million, a sharp contrast to where the company stood just four quarters ago. Looking at the EPS history, OPKO has now beaten analyst estimates in six of the last eight quarters, though the magnitude of this quarter's beat stands apart from anything in that recent run.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
The price reaction in the filing's immediate aftermath reflected the surprise: shares climbed from around $1.235 before the report was filed to $1.45 shortly after, suggesting the market had not priced in either the Nicoya deal or the scale of the revenue outperformance. Investors will likely watch whether the pharmaceutical segment can sustain profitability beyond this licensing-driven quarter.
Mentioned: OPK